Free Trial
Charles Zhu

Charles Zhu Analyst Performance

Managing Director, Senior Research Analyst at Lifesci Capital

Charles Zhu is a stock analyst at Lifesci Capital in the medical sector, covering 2 publicly traded companies. Over the past year, Charles Zhu has issued 3 stock ratings, including strong buy and hold recommendations. While full access to Charles Zhu's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Charles Zhu's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
3 Last 0 Years
Buy Recommendations
33.33% 1 Buy Ratings
Companies Covered
2 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy33.3%1 ratings
Buy0.0%0 ratings
Hold66.7%2 ratings
Sell0.0%0 ratings

Out of 3 total stock ratings issued by Charles Zhu at Lifesci Capital, the majority (66.7%) have been Hold recommendations, followed by 33.3% Strong Buy.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
2 companies

Charles Zhu, an analyst at Lifesci Capital, currently covers 2 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
2 companies
100.0%

Charles Zhu of Lifesci Capital specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
1 company
50.0%
MED - DRUGS
1 company
50.0%

About Charles Zhu

Charles Zhu is a Senior Research Analyst at LifeSci Capital. Prior to joining the firm in 2024, Charles was a Director and Senior Biotech Analyst at Guggenheim Securities, LLC, where he worked for over 5 years covering small- and mid-cap oncology stocks. Prior to Guggenheim, he was a Consultant at The Dedham Group, LLC, where he specialized in pharmaceutical drug pricing and market access across multiple therapeutic areas including oncology, inflammation, and neurology. Charles holds a PhD in Biomedical Engineering from Rutgers University, where his dissertation focused on Actinium-225 as a cancer therapeutic, as well as BS and MEng degrees from Cornell University. Charles holds the Series 7, 86, and 87.
Follow on LinkedIn

Charles Zhu's Ratings History at Lifesci Capital

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Merus N.V. stock logo
MRUS
Merus
9/30/2025Reiterated Rating$93.67$97.00Market Perform
Merus N.V. stock logo
MRUS
Merus
9/29/2025Downgrade$94.15Hold
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
6/18/2025Upgrade$13.27$22.00Strong-Buy